A Phase 1 Safety And Pharmacokinetic Study Of SU011248 [sunitinib] And Capecitabine In Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 May 2010
At a glance
- Drugs Sunitinib (Primary) ; Capecitabine
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 25 Nov 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 25 Nov 2008 Actual patient numbers and actual completion date added, as reported by ClinicalTrials.gov.
- 08 Sep 2008 Planned end date changed from 1 Jun 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.